Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Plus de 40 000 produits accessibles à 0€ de frais de courtage
Découvrir Boursomarkets
Fermer
Forum AMGEN
273.5400 (c) USD
+0.60% 
Ouverture théorique 286.3700
valeur indicative 255.8967 EUR
indice de référenceNASDAQ Composite

US0311621009 AMGN

NASDAQ données temps différé
Chargement...
  • ouverture

    272.1400

  • clôture veille

    271.9100

  • + haut

    274.4800

  • + bas

    271.0500

  • volume

    0

  • capital échangé

    0.00%

  • valorisation

    146 595 MUSD

  • dernier échange

    23.04.24 / 22:00:00

  • limite à la baisse

    Qu'est-ce qu'une limite à la hausse/baisse ?

    Fermer

    174.6600

  • limite à la hausse

    Qu'est-ce qu'une limite à la hausse/baisse ?

    Fermer

    0.0000

  • rendement estimé 2024

    3.56%

  • PER estimé 2024

    Qu'est-ce que le PER ?

    Fermer

    13.48

  • dernier dividende

    A quoi correspond le montant du dernier dividende versé ?

    Fermer

    -

  • date dernier dividende

    -

  • Éligibilité

    -

  • Risque ESG

    Qu'est-ce que le risque ESG ?

    Fermer

    23.8/100 (moyen)

  • + Portefeuille

  • + Liste

Retour au sujet AMGEN INC

AMGEN : A.shelves Irish manufact facility plans

05 oct. 2007 11:01

Much to Ireland's disappointment, Amgen said it would "postpone indefinitely" a planned €800 million manufacturing facility in County Cork. The biotech giant said that a review of its business plan and the evolving business environment led to the decision. All 75 jobs in Ireland will be eliminated. The facility was to bring 1,100 jobs to the country. Irish officials were quick to point out that Amgen's decision was related to the company's business goals and not to the economic environment in Ireland.

"We understand that this is a very disappointing development for our employees, the government, the neighbors around our site and the broader Cork community," said Mark Sawyer, general manager and vice president of Operations, Amgen Technology Ireland. Amgen said that it expects to maintain ownership of the site, though other sources say the biotech is likely to sell. Amgen is in the midst of a company-wide restructuring designed to cut about 14 percent of its workforce and cut a billion dollars in expenses.

- see the release on the decision
- read the report from the Irish Independent

Related Articles:
Amgen selects manufacturing site. Report
Rhode Island feeling effects of Amgen cuts. Report
At corporate HQ, Amgen drops the axe. Report
Amgen makes big workforce, budget cuts. Report
Ireland trumpets Pfizer biotech facility. Report

1 réponse

  • 05 octobre 2007 11:02


Signaler le message

Fermer

Qui a recommandé ce message ?

Fermer
Retour au sujet AMGEN INC

Mes listes

Cette liste ne contient aucune valeur.